A Phase II Randomized Trial of Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer (LUST)
Latest Information Update: 13 Dec 2024
At a glance
- Drugs Lutetium-177 zadavotide guraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Dec 2024 Planned End Date changed from 1 Apr 2028 to 1 Apr 2032.
- 10 Dec 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2027.
- 16 Nov 2023 Status changed from not yet recruiting to recruiting.